These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 38205507)

  • 1. Rituximab plus cyclophosphamide and dexamethasone
    Xiong W; Lyu R; Yu Y; Wang T; Yan Y; Wang Y; Liu W; An G; Deng S; Xu Y; Sui W; Huang W; Zou D; Wang J; Qiu L; Yi S
    Haematologica; 2024 May; 109(5):1614-1618. PubMed ID: 38205507
    [No Abstract]   [Full Text] [Related]  

  • 2. Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia.
    Paludo J; Abeykoon JP; Shreders A; Ansell SM; Kumar S; Ailawadhi S; King RL; Koehler AB; Reeder CB; Buadi FK; Dispenzieri A; Lacy MQ; Dingli D; Witzig TE; Go RS; Gonsalves WI; Kourelis T; Warsame R; Leung N; Habermann TM; Hayman S; Lin Y; Kyle RA; Rajkumar SV; Gertz MA; Kapoor P
    Ann Hematol; 2018 Aug; 97(8):1417-1425. PubMed ID: 29610969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenström macroglobulinemia: final analysis of a phase 2 study.
    Kastritis E; Gavriatopoulou M; Kyrtsonis MC; Roussou M; Hadjiharissi E; Symeonidis A; Repoussis P; Michalis E; Delimpasi S; Tsatalas K; Tsirigotis P; Vassou A; Vervessou E; Katodritou E; Gika D; Terpos E; Dimopoulos MA
    Blood; 2015 Sep; 126(11):1392-4. PubMed ID: 26359434
    [No Abstract]   [Full Text] [Related]  

  • 4. Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016.
    Kapoor P; Ansell SM; Fonseca R; Chanan-Khan A; Kyle RA; Kumar SK; Mikhael JR; Witzig TE; Mauermann M; Dispenzieri A; Ailawadhi S; Stewart AK; Lacy MQ; Thompson CA; Buadi FK; Dingli D; Morice WG; Go RS; Jevremovic D; Sher T; King RL; Braggio E; Novak A; Roy V; Ketterling RP; Greipp PT; Grogan M; Micallef IN; Bergsagel PL; Colgan JP; Leung N; Gonsalves WI; Lin Y; Inwards DJ; Hayman SR; Nowakowski GS; Johnston PB; Russell SJ; Markovic SN; Zeldenrust SR; Hwa YL; Lust JA; Porrata LF; Habermann TM; Rajkumar SV; Gertz MA; Reeder CB
    JAMA Oncol; 2017 Sep; 3(9):1257-1265. PubMed ID: 28056114
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Waldenström macroglobulinemia: my way.
    Gertz M
    Leuk Lymphoma; 2013 Mar; 54(3):464-71. PubMed ID: 22860921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunoglobulin M (IgM) multiple myeloma versus Waldenström macroglobulinemia: diagnostic challenges and therapeutic options: two case reports.
    Elba S; Castellino A; Soriasio R; Castellino C; Bonferroni M; Mattei D; Strola G; Drandi D; Mordini N; Foglietta M; Rapezzi D; Celeghini I; Grasso M; Giordano F; Fraternali Orcioni G; Massaia M
    J Med Case Rep; 2020 Jun; 14(1):75. PubMed ID: 32564775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Agranulocytosis Associated with Waldenström Macroglobulinemia.
    Vaxman I; Shepshelovich D; Hayman L; Raanani P; Lahav M
    Acta Haematol; 2018; 140(1):42-45. PubMed ID: 30114687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II Bayesian sequential clinical trial in advanced Waldenström macroglobulinemia patients treated with bortezomib: interest of addition of dexamethasone.
    Leblond V; Morel P; Dilhuidy MS; Leleu X; Soussain C; Leprête S; Dreyfus B; Dartigeas C; Mahé B; Anglaret B; Pégourié B; Besson C; Aurran T; Vekhoff A; Tournilhac O; Banos A; Oya H; Lejeune J; Ouzegdouh M; Chevret S;
    Leuk Lymphoma; 2017 Nov; 58(11):2615-2623. PubMed ID: 28395585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world treatment patterns and outcomes in a national study of veterans with Waldenström macroglobulinemia, 2006-2019.
    Chien HC; Morreall D; Patil V; Rasmussen KM; Yong CM; Li CY; Passey DG; Burningham Z; Sauer BC; Halwani AS
    Am J Hematol; 2021 Jun; 96(6):E184-E187. PubMed ID: 33606890
    [No Abstract]   [Full Text] [Related]  

  • 10. Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment-naïve patients with Waldenstrom macroglobulinemia.
    Paludo J; Abeykoon JP; Kumar S; Shreders A; Ailawadhi S; Gertz MA; Kourelis T; King RL; Reeder CB; Leung N; Kyle RA; Buadi FK; Habermann TM; Dingli D; Witzig TE; Dispenzieri A; Lacy MQ; Go RS; Lin Y; Gonsalves WI; Warsame R; Lust JA; Rajkumar SV; Ansell SM; Kapoor P
    Br J Haematol; 2017 Oct; 179(1):98-105. PubMed ID: 28786474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN).
    Dimopoulos MA; García-Sanz R; Gavriatopoulou M; Morel P; Kyrtsonis MC; Michalis E; Kartasis Z; Leleu X; Palladini G; Tedeschi A; Gika D; Merlini G; Kastritis E; Sonneveld P
    Blood; 2013 Nov; 122(19):3276-82. PubMed ID: 24004667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180.
    Treon SP; Ioakimidis L; Soumerai JD; Patterson CJ; Sheehy P; Nelson M; Willen M; Matous J; Mattern J; Diener JG; Keogh GP; Myers TJ; Boral A; Birner A; Esseltine DL; Ghobrial IM
    J Clin Oncol; 2009 Aug; 27(23):3830-5. PubMed ID: 19506160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BDR in newly diagnosed patients with WM: final analysis of a phase 2 study after a minimum follow-up of 6 years.
    Gavriatopoulou M; García-Sanz R; Kastritis E; Morel P; Kyrtsonis MC; Michalis E; Kartasis Z; Leleu X; Palladini G; Tedeschi A; Gika D; Merlini G; Sonneveld P; Dimopoulos MA
    Blood; 2017 Jan; 129(4):456-459. PubMed ID: 27872060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclophosphamide, bortezomib, and dexamethasone combination in waldenstrom macroglobulinemia.
    Leblebjian H; Noonan K; Paba-Prada C; Treon SP; Castillo JJ; Ghobrial IM
    Am J Hematol; 2015 Jun; 90(6):E122-3. PubMed ID: 25703132
    [No Abstract]   [Full Text] [Related]  

  • 15. Does Bortezomib-Dexamethasone-Rituximab-Cyclophosphamide Play a Role in the Treatment of Waldenström's Macroglobulinemia?
    Sarosiek S; Treon SP; Branagan AR; Castillo JJ
    J Clin Oncol; 2023 Aug; 41(24):4059-4060. PubMed ID: 37348023
    [No Abstract]   [Full Text] [Related]  

  • 16. Severe peripheral neuropathy following carfilzomib, rituximab, and dexamethasone for initial treatment of Waldenström's macroglobulinemia.
    Alfaraj WA; Cachia D; Tummala S; Thomas SK; Manasanch EE
    Ann Hematol; 2016 Jan; 95(2):347-8. PubMed ID: 26432713
    [No Abstract]   [Full Text] [Related]  

  • 17. Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma.
    Romaguera JE; Wang M; Feng L; Fayad LE; Hagemeister F; McLaughlin P; Rodriguez MA; Fanale M; Orlowski R; Kwak LW; Neelapu S; Oki Y; Pro B; Younes A; Samaniego F; Fowler N; Hartig K; Valentinetti M; Smith J; Ford P; Naig A; Medeiros LJ; Kantarjian HM; Goy A
    Cancer; 2018 Jun; 124(12):2561-2569. PubMed ID: 29723393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating low CD4
    Cao X; Kong YL; Wang L; Liang JH; Xia Y; Zhu HY; Fan L; Jiang SH; Liu H; Li JY; Xu W
    Ann Hematol; 2021 Apr; 100(4):995-1002. PubMed ID: 33651193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bortezomib-Dexamethasone, Rituximab, and Cyclophosphamide as First-Line Treatment for Waldenström's Macroglobulinemia: A Prospectively Randomized Trial of the European Consortium for Waldenström's Macroglobulinemia.
    Buske C; Dimopoulos MA; Grunenberg A; Kastritis E; Tomowiak C; Mahé B; Troussard X; Hajek R; Viardot A; Tournilhac O; Aurran T; Lepretre S; Zerazhi H; Hivert B; Leblond V; de Guibert S; Brandefors L; Garcia-Sanz R; Gomes da Silva M; Kimby E; Schmelzle B; Kaszynski D; Dreyhaupt J; Muche R; Morel P
    J Clin Oncol; 2023 May; 41(14):2607-2616. PubMed ID: 36763945
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complete remission of Schnitzler syndrome and Waldenström macroglobulinemia under rituximab-cyclophosphamide-dexamethasone.
    Aouba A; Pressiat C; Pricopi M; Georgin-Lavialle S; Boue F; Lievre-Castilla MA; Marfaing-Koka A; Prevot S; Decottignies A
    Dermatology; 2015; 230(1):18-22. PubMed ID: 25471063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.